These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18991331)

  • 1. E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas.
    De Meyer T; Bijsmans IT; Van de Vijver KK; Bekaert S; Oosting J; Van Criekinge W; van Engeland M; Sieben NL
    J Pathol; 2009 Jan; 217(1):14-20. PubMed ID: 18991331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
    Meinhold-Heerlein I; Bauerschlag D; Hilpert F; Dimitrov P; Sapinoso LM; Orlowska-Volk M; Bauknecht T; Park TW; Jonat W; Jacobsen A; Sehouli J; Luttges J; Krajewski M; Krajewski S; Reed JC; Arnold N; Hampton GM
    Oncogene; 2005 Feb; 24(6):1053-65. PubMed ID: 15558012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer.
    Reimer D; Sadr S; Wiedemair A; Goebel G; Concin N; Hofstetter G; Marth C; Zeimet AG
    Ann N Y Acad Sci; 2006 Dec; 1091():270-81. PubMed ID: 17341621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical molecular abnormalities in high-grade serous carcinoma of the ovary.
    Köbel M; Huntsman D; Gilks CB
    Expert Rev Mol Med; 2008 Aug; 10():e22. PubMed ID: 18671886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Bandiera E; Rossi E; Donzelli C; Pasinetti B; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2007 Mar; 196(3):245.e1-11. PubMed ID: 17346539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
    Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
    Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
    Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
    Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinately up-regulated genes in ovarian cancer.
    Hough CD; Cho KR; Zonderman AB; Schwartz DR; Morin PJ
    Cancer Res; 2001 May; 61(10):3869-76. PubMed ID: 11358798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
    Sayer RA; Lancaster JM; Pittman J; Gray J; Whitaker R; Marks JR; Berchuck A
    Gynecol Oncol; 2005 Feb; 96(2):355-61. PubMed ID: 15661221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.
    Tone AA; Begley H; Sharma M; Murphy J; Rosen B; Brown TJ; Shaw PA
    Clin Cancer Res; 2008 Jul; 14(13):4067-78. PubMed ID: 18593983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.
    Reimer D; Sadr S; Wiedemair A; Stadlmann S; Concin N; Hofstetter G; Müller-Holzner E; Marth C; Zeimet AG
    Clin Cancer Res; 2007 Jan; 13(1):144-51. PubMed ID: 17200349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs).
    Haller F; Löbke C; Ruschhaupt M; Cameron S; Schulten HJ; Schwager S; von Heydebreck A; Gunawan B; Langer C; Ramadori G; Sültmann H; Poustka A; Korf U; Füzesi L
    J Pathol; 2008 Jul; 215(3):253-62. PubMed ID: 18438954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
    Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel E2F1 target genes regulated in cell cycle-dependent and independent manners.
    Iwanaga R; Komori H; Ishida S; Okamura N; Nakayama K; Nakayama KI; Ohtani K
    Oncogene; 2006 Mar; 25(12):1786-98. PubMed ID: 16288221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer.
    Sawiris GP; Sherman-Baust CA; Becker KG; Cheadle C; Teichberg D; Morin PJ
    Cancer Res; 2002 May; 62(10):2923-8. PubMed ID: 12019173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.